Resectable intermediate to high-risk clear cell RCC (according to RECIST 1.1) that can be biopsied, no history of distant metastases, naïve for CTLA-4/PD-1/PD-L1/LAG-3 directed immunotherapy, and more than 18 years old

• Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for rec … Recruitment ended
  2024-515514-40-00 4 2022-01-05

Showing 1–1 of 1 trials